Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Publication Title
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Document Type
Article
Publication Date
6-16-2024
Keywords
washington; swedish; swedish cancer
Abstract
PURPOSE: We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg and 200 mg doses of linvoseltamab, a B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM).
METHODS: Phase II eligible patients had RRMM that either progressed on/after ≥three lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody or was triple-class (PI/IMiD/anti-CD38) refractory. Phase II treatment was once a week through week 14 and then once every 2 weeks. Phase II 200 mg patients who achieved a ≥very good partial response by week 24 received linvoseltamab once every 4 weeks. The primary end point in phase II was overall response rate (ORR).
RESULTS: Among the 117 patients treated with 200 mg, the median age was 70 years, 39% had high-risk cytogenetics, and 28% had penta-refractory disease. At a median follow-up of 14.3 months, the ORR was 71%, with 50% achieving ≥complete response (CR). In 104 patients treated with 50 mg at a median follow-up of 7.4 months, the ORR was 48%, with 21% achieving ≥CR. The median duration of response (DOR) for 200 mg patients (n = 83) was 29.4 months (95% CI, 19.2 to not evaluable). Among 200 mg patients, the most common adverse events included cytokine release syndrome (35.0% Gr1, 10.3% Gr2, 0.9% Gr3), neutropenia (0.9% Gr2, 18.8% Gr3, 23.1% Gr4), and anemia (3.4% Gr1, 4.3% Gr2, 30.8% Gr3). Immune effector cell-associated neurotoxicity syndrome occurred in 7.7% of patients (2.6% each Gr1, Gr2, Gr3). Infections were reported in 74.4% of patients (33.3% Gr3, 2.6% Gr4); infection frequency and severity declined over time.
CONCLUSION: Linvoseltamab 200 mg induced deep and durable responses, with a median DOR of 29.4 months, in patients with RRMM with an acceptable safety profile.
Clinical Institute
Cancer
Specialty
Oncology
Recommended Citation
Bumma, Naresh; Richter, Joshua; Jagannath, Sundar; Lee, Hans C; Hoffman, James E; Suvannasankha, Attaya; Zonder, Jeffrey A; Shah, Mansi R; Lentzsch, Suzanne; Baz, Rachid; Maly, Joseph J; Namburi, Swathi; Pianko, Matthew J; Ye, Jing Christine; Wu, Ka Lung; Silbermann, Rebecca; Min, Chang-Ki; Vekemans, Marie-Christiane; Munder, Markus; Byun, Ja Min; Martínez-Lopez, Joaquín; Cassady, Kaniel; DeVeaux, Michelle; Chokshi, Dhruti; Boyapati, Anita; Hazra, Anasuya; Yancopoulos, George D; Sirulnik, L Andres; Rodriguez Lorenc, Karen; Kroog, Glenn S; Houvras, Yariv; and Dhodapkar, Madhav V, "Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma." (2024). Articles, Abstracts, and Reports. 8912.
https://digitalcommons.providence.org/publications/8912